Graves’ Ophthalmopathy - Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Graves’ Ophthalmopathy - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Graves’ Ophthalmopathy Understanding
Graves' Ophthalmopathy also known as Graves' eye disease or Graves’ Orbitopathy is a problem that usually develops in people with an overactive thyroid caused by Graves’ disease. It is an autoimmune condition where the body's immune system produces an antibody to cells in the thyroid gland causing an overproduction of thyroid hormones. It appears that the same antibody that can cause thyroid dysfunction may also have an "attraction"" to tissues surrounding the eyes causing the onset of Graves' Ophthalmopathy. The disease is categorized as mild, moderate, and severe. Some common symptoms of Graves’ Ophthalmopathy includes, feeling of irritation or grittiness in the eyes, redness or inflammation of the conjunctiva (the white part of the eyeball), excessive tearing or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision. In more advanced eye disease there may also be decreased eye movement and eyelids, incomplete closure of the eye with corneal ulceration, compression of the optic nerve and rarely, loss of vision.
Graves’ Ophthalmopathy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Graves’ Ophthalmopathy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Graves’ Ophthalmopathy pipeline report covers 6+ companies. Some of the key players include HanAll Biopharma (HL 161), Horizon Therapeutics (Teprotumumab) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Graves’ Ophthalmopathy Analytical Perspective by DelveInsight
Scope of the report
"Graves’ Ophthalmopathy - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Graves’ Ophthalmopathy Understanding
Graves' Ophthalmopathy also known as Graves' eye disease or Graves’ Orbitopathy is a problem that usually develops in people with an overactive thyroid caused by Graves’ disease. It is an autoimmune condition where the body's immune system produces an antibody to cells in the thyroid gland causing an overproduction of thyroid hormones. It appears that the same antibody that can cause thyroid dysfunction may also have an "attraction"" to tissues surrounding the eyes causing the onset of Graves' Ophthalmopathy. The disease is categorized as mild, moderate, and severe. Some common symptoms of Graves’ Ophthalmopathy includes, feeling of irritation or grittiness in the eyes, redness or inflammation of the conjunctiva (the white part of the eyeball), excessive tearing or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision. In more advanced eye disease there may also be decreased eye movement and eyelids, incomplete closure of the eye with corneal ulceration, compression of the optic nerve and rarely, loss of vision.
Graves’ Ophthalmopathy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Graves’ Ophthalmopathy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Graves’ Ophthalmopathy pipeline report covers 6+ companies. Some of the key players include HanAll Biopharma (HL 161), Horizon Therapeutics (Teprotumumab) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Graves’ Ophthalmopathy Analytical Perspective by DelveInsight
- In-depth Graves’ Ophthalmopathy Commercial Assessment of products
- Graves’ Ophthalmopathy Clinical Assessment of products
Scope of the report
- The Graves’ Ophthalmopathy report provides an overview of therapeutic pipeline activity for Graves’ Ophthalmopathy across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Graves’ Ophthalmopathy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Graves’ Ophthalmopathy Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Graves’ Ophthalmopathy
- Establish a comprehensive understanding of the current pipeline scenario across Graves’ Ophthalmopathy to formulate effective R&D strategies
- Assess challenges and opportunities that influence Graves’ Ophthalmopathy R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Graves’ Ophthalmopathy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Graves’ Ophthalmopathy to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. GRAVES’ OPHTHALMOPATHY
2.1. Graves’ Ophthalmopathy Disease Overview
2.2. Graves’ Ophthalmopathy History
2.3. Graves’ Ophthalmopathy Symptoms
2.4. Graves’ Ophthalmopathy Causes
2.5. Graves’ Ophthalmopathy Pathophysiology
2.6. Graves’ Ophthalmopathy Diagnosis
2.6.1. Diagnostic Guidelines
3. GRAVES’ OPHTHALMOPATHY CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. GRAVES’ OPHTHALMOPATHY- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Graves’ Ophthalmopathy companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Graves’ Ophthalmopathy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Graves’ Ophthalmopathy Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. GRAVES’ OPHTHALMOPATHY PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. GRAVES’ OPHTHALMOPATHY-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. HL 161- HanAll Biopharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Teprotumumab- Horizon Therapeutics
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. GRAVES’ OPHTHALMOPATHY KEY COMPANIES
8.1. BTG
8.2. Horizon Therapeutics
8.3. HanAll Biopharma
8.4. Enceladus Pharmaceuticals
8.5. Pfizer
8.6. Shanghai Henlius Biotech
9. GRAVES’ OPHTHALMOPATHY KEY PRODUCTS
9.1. Otelixizumab
9.2. Teprotumumab
9.3. HL 161
9.4. Liposome encapsulated prednisolone
9.5. Celecoxib
9.6. Rituximab biosimilar
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. GRAVES’ OPHTHALMOPATHY- UNMET NEEDS
12. GRAVES’ OPHTHALMOPATHY- FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. GRAVES’ OPHTHALMOPATHY
2.1. Graves’ Ophthalmopathy Disease Overview
2.2. Graves’ Ophthalmopathy History
2.3. Graves’ Ophthalmopathy Symptoms
2.4. Graves’ Ophthalmopathy Causes
2.5. Graves’ Ophthalmopathy Pathophysiology
2.6. Graves’ Ophthalmopathy Diagnosis
2.6.1. Diagnostic Guidelines
3. GRAVES’ OPHTHALMOPATHY CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. GRAVES’ OPHTHALMOPATHY- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Graves’ Ophthalmopathy companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Graves’ Ophthalmopathy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Graves’ Ophthalmopathy Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. GRAVES’ OPHTHALMOPATHY PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. GRAVES’ OPHTHALMOPATHY-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. HL 161- HanAll Biopharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Teprotumumab- Horizon Therapeutics
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. GRAVES’ OPHTHALMOPATHY KEY COMPANIES
8.1. BTG
8.2. Horizon Therapeutics
8.3. HanAll Biopharma
8.4. Enceladus Pharmaceuticals
8.5. Pfizer
8.6. Shanghai Henlius Biotech
9. GRAVES’ OPHTHALMOPATHY KEY PRODUCTS
9.1. Otelixizumab
9.2. Teprotumumab
9.3. HL 161
9.4. Liposome encapsulated prednisolone
9.5. Celecoxib
9.6. Rituximab biosimilar
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. GRAVES’ OPHTHALMOPATHY- UNMET NEEDS
12. GRAVES’ OPHTHALMOPATHY- FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Graves’ Ophthalmopathy Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Graves’ Ophthalmopathy Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Graves’ Ophthalmopathy Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Graves’ Ophthalmopathy Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Graves’ Ophthalmopathy companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Graves’ Ophthalmopathy Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
BTG
Horizon Therapeutics
HanAll Biopharma
Yuhan
Enceladus Pharmaceuticals
Pfizer
Shanghai Henlius Biotech
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Graves’ Ophthalmopathy companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Graves’ Ophthalmopathy Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
BTG
Horizon Therapeutics
HanAll Biopharma
Yuhan
Enceladus Pharmaceuticals
Pfizer
Shanghai Henlius Biotech
